Olpres
Generic Name
Olmesartan Medoxomil
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olpres 40 mg tablet | ৳ 15.00 | ৳ 150.00 |
Description
Overview of the medicine
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) primarily used to treat high blood pressure (hypertension) by relaxing blood vessels, allowing blood to flow more easily.
Uses & Indications
Dosage
Adults
The usual recommended starting dose is 20 mg once daily. The dose can be increased to a maximum of 40 mg once daily if blood pressure is not adequately controlled.
Elderly
No dosage adjustment is usually necessary for elderly patients unless they have severe renal or hepatic impairment.
Renal_impairment
For patients with moderate to severe renal impairment (creatinine clearance <40 mL/min), the initial dose is 10 mg once daily. Close monitoring of renal function and serum potassium is recommended.
How to Take
Take orally once daily with or without food. It should be swallowed whole with water. It is important to take it at approximately the same time each day.
Mechanism of Action
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan during absorption. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland), thereby inhibiting the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This leads to vasodilation and a reduction in blood pressure.
Pharmacokinetics
Onset
Antihypertensive effect is evident within 1 week, with maximum reduction achieved within 2 weeks. Full blood pressure lowering effect may take up to 8 weeks.
Excretion
Approximately 35-50% is eliminated renally (glomerular filtration), and the remainder via biliary/fecal route.
Half life
Approximately 13 hours.
Absorption
Rapidly and completely absorbed from the GI tract after hydrolysis to active olmesartan. Absolute bioavailability is approximately 26%. Peak plasma concentration is reached within 1-2 hours.
Metabolism
The medoxomil moiety is completely hydrolyzed to active olmesartan in the GI tract. Olmesartan itself is not significantly metabolized.
Side Effects
Contraindications
- Hypersensitivity to olmesartan medoxomil or any component of the formulation.
- Pregnancy (second and third trimesters) due to fetal toxicity.
- Concomitant use with aliskiren in patients with diabetes or moderate to severe renal impairment (GFR <60 mL/min/1.73m²).
- Biliary obstruction.
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity have been reported with ARBs. Monitor serum lithium levels.
Aliskiren
Increased risk of hypotension, hyperkalemia, and renal impairment when co-administered in patients with diabetes or renal impairment.
NSAIDs (Non-steroidal anti-inflammatory drugs)
May reduce the antihypertensive effect of olmesartan and increase the risk of renal function deterioration.
Potassium-sparing diuretics/Potassium supplements/Salt substitutes containing potassium
Increased risk of hyperkalemia. Monitor serum potassium levels.
Storage
Store in a dry place below 30°C, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension (low blood pressure) and tachycardia (rapid heart rate); bradycardia (slow heart rate) could also occur. Treatment is symptomatic and supportive. If ingestion is recent, gastric lavage may be considered. Hemodialysis is unlikely to remove olmesartan effectively.
Pregnancy & Lactation
Pregnancy: Contraindicated in the second and third trimesters due to potential fetal toxicity (renal dysfunction, oligohydramnios, skeletal deformations, fetal death). Lactation: It is unknown whether olmesartan is excreted in human breast milk. Due to the potential for adverse effects on the nursing infant, it is not recommended during lactation.
Side Effects
Contraindications
- Hypersensitivity to olmesartan medoxomil or any component of the formulation.
- Pregnancy (second and third trimesters) due to fetal toxicity.
- Concomitant use with aliskiren in patients with diabetes or moderate to severe renal impairment (GFR <60 mL/min/1.73m²).
- Biliary obstruction.
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity have been reported with ARBs. Monitor serum lithium levels.
Aliskiren
Increased risk of hypotension, hyperkalemia, and renal impairment when co-administered in patients with diabetes or renal impairment.
NSAIDs (Non-steroidal anti-inflammatory drugs)
May reduce the antihypertensive effect of olmesartan and increase the risk of renal function deterioration.
Potassium-sparing diuretics/Potassium supplements/Salt substitutes containing potassium
Increased risk of hyperkalemia. Monitor serum potassium levels.
Storage
Store in a dry place below 30°C, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension (low blood pressure) and tachycardia (rapid heart rate); bradycardia (slow heart rate) could also occur. Treatment is symptomatic and supportive. If ingestion is recent, gastric lavage may be considered. Hemodialysis is unlikely to remove olmesartan effectively.
Pregnancy & Lactation
Pregnancy: Contraindicated in the second and third trimesters due to potential fetal toxicity (renal dysfunction, oligohydramnios, skeletal deformations, fetal death). Lactation: It is unknown whether olmesartan is excreted in human breast milk. Due to the potential for adverse effects on the nursing infant, it is not recommended during lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from the date of manufacture.
Availability
Pharmacies and hospitals
Approval Status
Approved by regulatory authorities worldwide
Patent Status
Generic versions available, original patent expired
Clinical Trials
Olmesartan has been studied in numerous clinical trials to evaluate its efficacy and safety in treating hypertension and reducing cardiovascular risk. Key studies include the ROADMAP trial (Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention) and the ESPRIT study (Evaluation of Safety and Pharmacodynamics of Olmesartan in Renal Impairment Trial).
Lab Monitoring
- Blood pressure should be monitored regularly.
- Renal function (BUN, serum creatinine, GFR) should be assessed periodically, especially in patients with pre-existing renal impairment or during concomitant use with NSAIDs.
- Serum potassium levels should be monitored periodically, particularly in patients with renal impairment, heart failure, or those taking potassium-sparing diuretics or potassium supplements.
Doctor Notes
- Regularly monitor blood pressure, renal function (creatinine, BUN), and serum potassium levels, especially in patients with pre-existing renal impairment, heart failure, or those concomitantly on potassium-sparing diuretics.
- Counsel patients on the importance of consistent medication adherence and lifestyle modifications.
- Advise women of childbearing potential about the risks of fetal toxicity and the need for effective contraception or alternative antihypertensive therapy if planning pregnancy.
Patient Guidelines
- Take this medicine exactly as prescribed by your doctor, usually once daily.
- Do not stop taking Olpres suddenly without consulting your doctor, as this may cause your blood pressure to rise.
- Inform your doctor about all other medications, supplements, and herbal products you are taking.
- Report any signs of swelling of the face, lips, tongue, or throat (angioedema) immediately.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Olpres may cause dizziness or fatigue, especially at the start of treatment or when changing dosage. If affected, avoid driving or operating heavy machinery until you know how the medicine affects you.
Lifestyle Advice
- Maintain a healthy lifestyle that includes a balanced diet low in sodium, regular physical activity, and weight management.
- Limit alcohol consumption.
- Quit smoking, as it significantly increases cardiovascular risk.
- Manage stress effectively.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olpres Brand
Other medicines available under the same brand name
